Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -76.82% | -86.68% | -62.41% | -104.07% | 17.03% |
| Total Depreciation and Amortization | 8.70% | -25.23% | -62.52% | -58.10% | -56.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 120.94% | 405.25% | 1,199.47% | 17,441.67% | -0.43% |
| Change in Net Operating Assets | 3.28% | -6.75% | -106.92% | 102.47% | -39.35% |
| Cash from Operations | -114.90% | 13.33% | -234.42% | 38.68% | -28.67% |
| Capital Expenditure | -- | 93.80% | 91.64% | 73.13% | 70.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,219.24% | -- | -5,452.38% | -- | -- |
| Cash from Investing | -1,258.23% | -168.61% | -870.51% | -4,941.79% | 23.81% |
| Total Debt Issued | 408.16% | -875.88% | -- | -- | -99.12% |
| Total Debt Repaid | 91.91% | -150.60% | 60.41% | 50.15% | -1,136.58% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 95.61% | -385.85% | 339.96% | 50.50% | -233.90% |
| Foreign Exchange rate Adjustments | -519.48% | -101.14% | -1,118.75% | 164.74% | 569.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -313.44% | -74.75% | -296.81% | 9.35% | -460.08% |